Current therapies for malignant pleural mesothelioma

Environmental Health and Preventive Medicine

Volumn 13, Issue 2, 2008, Pages 75-83

  Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Asbestos; Extrapleural pneumonectomy; Mesothelioma; Pemetrexed

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA INTERFERON; ASBESTOS; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; FOLIC ACID; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PEMETREXED; RALTITREXED; TRIMETREXATE;

ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; OCCUPATIONAL EXPOSURE; PLEURA MESOTHELIOMA; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SEX DIFFERENCE; SURVIVAL TIME; THORAX PAIN;

EID: 49549093577     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-007-0016-7     Document Type: Conference Paper

References (44)

1. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest. 1995;108:1122-8.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Symanowski J, Denham C, Kaukel E, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
3. Van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RV, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung-Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881-9.
4. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer. 2004;5:290-8.
5. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer. 2004;455:S103-19.
6. Steele JPC Rudd RM. Systemic chemotherapy for malignant pleural mesothelioma. In: O'Byrne K, Rusch V, editors. Malignant Pleural Mesothelioma. New York: Oxford; 2006. p. 298-313.
7. Berghmans T,Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systemic review of the literature with meta-analysis. Lung Cancer. 2002;38:111-21.
8. Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer. 2003;88:167-74.
9. ®-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemoimmunotherapy in mesothelioma. Eur J Cancer. 2000;36:1514-21.
10. Schuette W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer. 2003;4:294-7.
11. Fennell DA, Steele C, Shamush J, Sheaff MT, Evans MT, Goonewardene TI, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer. 2005;47:277-81.
12. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol. 1996;14:1007-17.
13. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993;11:1559-65.
14. Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer. 1997;79:1897-902.
15. Kindler HI, Herndon JE, Zhang C, Green MR. Cancer and Leukemia Group B. Irinotecan for malignant mesothelioma. A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005;48:423-8.
16. Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma. A pilot phase II clinical trial and pharmacokinetic profile. Cancer. 1999;85:2375-84.
17. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest. 2003;21:682-9.
18. Fennell DA, Steele JP, Shamash J. A phase II study of irinotecan, cisplatin, and mitomycin C in malignant pleural mesothelioma. Lung Cancer. 2003;41(Suppl 2):S221b.
19. Halme M, Knuuttila A, Vehmas T, Tammilehto L, Mantyla M, Salo J, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer. 1999;80:1781-5.
20. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant pleural mesothelioma: a phase II study. J Clin Oncol. 1999;17:25-30.
21. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491-6.
22. van Haarst JMW, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86:342-5.
23. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556-61.
24. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pwel J, Kortsik C, et al. Second-line (post-study) chemotherapy received by patients treated in the phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16:923-7.
25. Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer. 2005:48:429-34.
26. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer. 2004;43:63-9.
27. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new response evaluation criteria in solid tumors (RECIST) in patients with malignant plural mesothelioma: report of four cases. Lung Cancer. 2004;43:71-4.
28. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257-60.
29. Armato III SG, MacMahon H, Oxnard GR, Croteau CL, Vogelzang NJ. Radiologic assessment of mesothelioma. In: Pas HI, Vogelzang NJ, Carbone M, editors. Malignant Mesothelioma. New York: Springer; 2005. p. 433-53.
30. Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587-93.
31. Carmichael J, Degraff WG, Gamson J, Russo D, Gazdar AF, Levitt ML, et al. Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol. 1989;25:527-34.
32. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108:754-8.
33. do Graat-Strukowska, van der Zee, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura-a single-institute experience with 189 patients. Int J Radit Oncol Biol Phys. 1999;43:511-6.
34. Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, et al. A randomized trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91:9-10.
35. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788-95.
36. Zierhut D, Gutwein S, Munter MW, Woger H, Debus J. Radiation therapy of mesothelioma: the Heidelberg experience and future aspects. Lung Cancer. 2004;455:585-91.
37. Forster KM, Smythe WR, Starkschall G, Liao Z, Takanaka T, Kelly JF, et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys. 2003;55:606-16.
38. Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65:640-5.
39. Jang SY, Liu HH, Wang X, Vassiliev ON, Siebers JV, Dong L, et al. Dosimetric verification for intensity-modulated radiotherapy of thoracic cancers using experimental and Monte Carlo approaches. Int J Radat Oncol Biol Phys. 2006;66:939-48.
40. Kukreja J, Jaklitsch MT, Wiener DC, Sugarbaker DJ, Burgers S, Baas P. Malignant pleural mesothelioma: overview of the North American and European experience. Thorac Surg Clin. 2004;14:435-45.
41. Treasure T, Waller D, Swift S, Peto J. Radical surgery for mesothelioma. BMJ. 2004;328:237-8.
42. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM,Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Sur. 1999;117:54-63; discussion 63-5.
43. McCormack PM, Nagasaki F, Hilaris BS, Martini N. Surgical treatment of pleural mesothelioma. J Thorac Cardiovasc Sur. 1982;84:834-42.
44. Weder W, Kestenholz P, Tavema C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451-7.